CT-388 GLP-1/GIP & Petrelintide — PatSnap Eureka
CT-388 GLP-1/GIP Dual Agonist & Petrelintide: The Next Obesity Frontier
Roche's CT-388 Phase II readout and Zealand Pharma's petrelintide amylin partnership are reshaping the next generation of obesity therapeutics. Explore the patent landscape, clinical data signals, and competitive dynamics powering this inflection point.
Why GLP-1/GIP Dual Agonism Outperforms Mono-Agonism in Obesity
The obesity treatment landscape underwent a fundamental shift with the approval of tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Phase 3 clinical trials demonstrated body weight reduction of up to 22.5% with tirzepatide 15 mg in people with obesity — a benchmark that single-mechanism GLP-1 agonists could not match. Tirzepatide represents a new class of 'twincretin' medications and has been approved for both type 2 diabetes and obesity.
CT-388, Roche's GLP-1/GIP dual agonist, is currently in Phase II clinical development targeting this same dual-receptor mechanism. Patent analysis from PatSnap analytics reveals that Chugai Pharmaceutical (a Roche subsidiary) has filed GLP-1/GIP dual agonist peptide patents covering metabolic disorders including obesity, type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD). These compounds are engineered to display selectivity for both the GIP receptor and the GLP-1 receptor.
Literature analysis published in 2024 confirmed that dual GLP-1/GIP agonists reduce liver lipid droplets and alter gene expression in the liver by acting through the GLP-1 receptor, not the GIP receptor — a mechanistic insight with implications for CT-388's differentiation strategy and potential NASH label expansion. For the broader regulatory context, the FDA has been actively reviewing next-generation obesity treatments beyond GLP-1 mono-agonism.
Novo Nordisk's patent filings covering acylated GLP-1/GIP dual agonists with fatty acid linkers enabling once-weekly administration demonstrate that extended half-life formulation is a key competitive parameter in this class — a design consideration relevant to CT-388's clinical profile and commercial positioning.
Obesity Drug Efficacy and Patent Filing Landscape
Weight loss benchmarks from published clinical data and Zealand Pharma's amylin patent filing timeline — sourced from PatSnap Eureka patent and literature analysis.
Body Weight Loss by Drug Class / Candidate
Dual GLP-1/GIP agonists achieve the highest weight loss at up to 22.5%, followed by amylin+GLP-1 combination at 15.6%, and amylin monotherapy at 10.8%.
Zealand Pharma Amylin Patent Filing Timeline
Zealand Pharma has built a dense amylin analogue patent estate from 2019 through 2022, covering obesity treatment and synergistic combinations — underpinning petrelintide's IP position.
Zealand Pharma's Petrelintide: Amylin Agonism as Obesity Combination Backbone
Zealand Pharma's amylin analogue platform, underpinning petrelintide, is built on a deep patent estate and a scientifically validated complementary mechanism to GLP-1 agonism.
Distinct Brain Pathways Enable Synergistic Weight Loss
GLP-1 acts primarily in the hindbrain by activating GLP-1 receptors in the area postrema and the nucleus tractus solitarius, whereas amylin acts primarily through the area postrema and the lateral parabrachial nucleus. Both mechanisms signal via the area postrema, but activate distinct neuronal populations. The combination of amylin receptor agonism with GLP-1 receptor agonism is predicted to complement and potentially synergize to inhibit food intake, increase energy expenditure, and reduce body weight. This scientific rationale underpins Zealand's partnership strategy with major pharma partners.
Complementary neuronal activationZealand's Amylin Patent Portfolio Spans 2019–2022
Zealand Pharma holds multiple WO patent families covering amylin analogues for obesity treatment: WO2019/243491 (amylin analogues for obesity), WO2020 (amylin analogues), WO2021/032792 (amylin analogue continuation), and two WO2022 publications titled "Novel Peptide Analogues" which explicitly reference WO2021/032792. These patents cover amylin receptor agonist analogues with improved half-life and solubility versus native human amylin, which is not therapeutically useful because of its tendency to form amyloid deposits. The patent analytics show a clear IP accumulation strategy.
5+ patent families since 2019Synergistic Weight Reduction with GLP-1, GIP, and Other Agents
Zealand's 2019 patent (WO2019/243491) explicitly describes that a synergistic weight reducing effect may be achieved by administering an amylin analogue in combination with another agent selected from: GLP-1 agonists, GIP agonists, GLP-2 agonists, NPY receptor antagonists, PYY agonists, melanocortin receptor agonists, leptin receptor agonists, sodium glucose cotransporter (SGLT) inhibitors, or combinations thereof. This broad combination IP positions petrelintide as a versatile backbone for next-generation obesity regimens, including potential combination with CT-388. The EMA has been tracking combination obesity therapy development closely.
Broad combination IP claimedNovo Nordisk's CagriSema Sets the Combination Benchmark
Cagrilintide, Novo Nordisk's long-acting amylin analogue, exhibited dose-dependent weight loss of up to 10.8% in a Phase 2 trial. In combination with semaglutide 2.4 mg, CagriSema reduced body weight by up to 15.6% at 20 weeks in an exploratory Phase 2 trial. Amylin acts as a satiety hormone co-secreted with insulin from pancreatic beta cells, activating specific amylin receptors in the area postrema and lateral parabrachial nucleus of the brain. These results validate the amylin+GLP-1 combination rationale that Zealand's petrelintide is pursuing. New-generation amylin analogues are designed with a longer half-life and more solubility versus pramlintide (approved for diabetes). See ClinicalTrials.gov for active trial registrations.
CagriSema: 15.6% BWL at 20 weeksNext-Generation Obesity Pipeline: Key Candidates and Mechanisms
A structured view of the leading obesity drug candidates, their mechanisms, assignees, and clinical stage — sourced from patent and literature analysis via PatSnap Eureka.
Need Real-Time Pipeline Monitoring?
PatSnap Eureka tracks patent filings, clinical updates, and partnership signals across the obesity landscape automatically.
What the CT-388 Phase II Readout and Petrelintide Partnership Signal for the Field
Key strategic takeaways derived from patent analysis and published literature on next-generation obesity drug development.
Dual Agonism Is the Validated Baseline — Not the Ceiling
Tirzepatide's approval established that dual GLP-1/GIP agonism outperforms GLP-1 mono-agonism. CT-388's Phase II positions Roche to compete in this validated class. But the literature is clear: many next-generation obesity treatments that engage additional metabolic hormone receptors are currently being developed, including triple agonists activating GLP-1, GIP and glucagon receptors, and amylin analogues. Dual agonism is the floor, not the ceiling, of next-generation obesity medicine.
Amylin's Complementary Neuroscience Justifies the Zealand-Roche Bet
The scientific rationale for combining amylin agonism with GLP-1 agonism is mechanistically distinct from simply adding another incretin. GLP-1 acts primarily in the hindbrain via the area postrema and nucleus tractus solitarius. Amylin acts via the area postrema and the lateral parabrachial nucleus — distinct neuronal populations. This complementarity is predicted to synergize to inhibit food intake, increase energy expenditure, and reduce body weight, justifying Zealand's petrelintide partnership strategy with Roche.
Key Signals to Watch: CT-388, Petrelintide, and the Obesity Combination Race
Critical monitoring signals for R&D, BD, and investment teams tracking the CT-388 Phase II readout and petrelintide partnership developments.
CT-388, Petrelintide & GLP-1/GIP Obesity Pipeline — Key Questions Answered
CT-388 is a GLP-1/GIP dual agonist peptide in Phase II clinical development for obesity. It is being developed by Roche and targets both the GLP-1 receptor and the GIP receptor simultaneously, a mechanism class validated by tirzepatide (Eli Lilly), the first approved dual GLP-1/GIP receptor agonist.
Petrelintide is an amylin receptor agonist analogue developed by Zealand Pharma for the treatment of obesity. Unlike pramlintide (approved for diabetes), petrelintide is designed with a longer half-life and greater solubility, enabling less frequent dosing. Zealand Pharma's patent portfolio covers amylin analogues for obesity, including synergistic combinations with GLP-1 agonists, GIP agonists, and other metabolic agents.
GLP-1 acts primarily in the hindbrain by activating GLP-1 receptors in the area postrema and the nucleus tractus solitarius, whereas amylin acts primarily through the area postrema and the lateral parabrachial nucleus. Both mechanisms signal via the area postrema, but activate distinct neuronal populations. The combination of amylin receptor agonism with GLP-1 receptor agonism is predicted to complement and potentially synergize to inhibit food intake, increase energy expenditure, and reduce body weight.
Phase 3 clinical trials have demonstrated body weight reduction of up to 22.5% with tirzepatide 15 mg in people with obesity. Dual GLP-1/GIP agonists have shown greater weight loss compared to GLP-1 mono-agonists. Tirzepatide represents a new class of 'twincretin' medications and has been approved for both type 2 diabetes and obesity.
Zealand Pharma holds multiple patent families covering amylin analogues for obesity treatment, including WO2019/243491, WO2021/032792, and subsequent continuation applications published in 2022. These patents cover amylin receptor agonist analogues and their use in combination with GLP-1 agonists, GIP agonists, GLP-2 agonists, NPY receptor antagonists, PYY agonists, melanocortin receptor agonists, leptin receptor agonists, and SGLT inhibitors to achieve synergistic weight reduction.
Many next-generation obesity treatments are in clinical development, including triple agonists activating GLP-1, GIP and glucagon receptors, and amylin analogues. Neuropeptide Y receptor antagonists, peptide YY analogues, and melanocortin 4 receptor agonists are also being evaluated. Emerging multi-agonists including triple agonists (GLP-1/GIP/glucagon) and other combinations including amylin, NPY/PYY, and others are under active investigation.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka AI About Obesity Drug PatentsAccelerate Your Obesity Pipeline Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track CT-388, petrelintide, and the next-generation obesity drug landscape.
References
- GLP-1/GIP Dual Agonist Peptides for Treatment of Metabolic Disorders — Chugai Pharmaceutical, WO patent, 2023
- Dual GLP-1/GIP receptor agonist treatment improves lipid droplet morphology and gene expression in the liver of obese mice via GLP-1 receptor — Published 2024
- Novel Peptide Analogues (Amylin Receptor Agonist Analogues) — Zealand Pharma, WO patent, 2022
- Novel Peptide Analogues — Zealand Pharma, WO patent, 2022
- GLP-1 receptor agonist and dual GLP-1/GIP receptor agonist's weight loss effects — Published 2024
- The next generation of obesity treatments: Beyond GLP-1 receptor agonists — Published 2024
- GIP Agonists and Combined GIP/GLP-1 Agonists for the Treatment of Metabolic Diseases — Novo Nordisk, WO patent, 2020
- Acylated GLP-1/GIP Dual Agonists — Novo Nordisk, WO patent, 2022
- Methods of Treating Metabolic Diseases with a GLP-1 Receptor Agonist and a GIP Receptor Agonist — Eli Lilly, WO patent, 2020
- Tirzepatide: A novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity — Published 2022
- Amylin and its Analogues: A Friend or Foe for the Management of Diabetes Mellitus and Obesity? — Published 2023
- Amylin Analogues — Zealand Pharma, WO patent, 2021
- Amylin Analogues for Treatment of Obesity — Zealand Pharma, WO patent, 2019
- Amylin Analogues — Zealand Pharma, WO patent, 2020
- Combination of amylin receptor agonism and GLP-1 receptor agonism — complementary mechanisms to boost weight loss — Published 2023
- Cagrilintide: A Long-Acting Amylin Analogue for the Management of Obesity — Published 2022
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.